The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
BRINEURA (BioMarin Pharmaceutical Australia Pty Ltd)
Product name
BRINEURA
Date registered
Evaluation commenced
Decision date
Approval time
129 working days (255)
Active ingredients
cerliponase alfa (rch)
Registration type
NCE/NBE
Indication
BRINEURA (solution for injection) is indicated for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency.